Abstract
Protein kinase C theta (PKC-) is a key kinase in mediating T cell receptor (TCR) signals. PKC- activated by T cell receptor (TCR) engagement translocates to immunological synapses and regulates the activation of transcriptional factors NF-κB, AP-1, and NFAT. These transcription factors then activate target genes such as IL-2. T cells deficient in PKC- display defects in T cell activation, survival, activation-induced cell death, and the differentiation into inflammatory T cells, both in vitro and in vivo. Since these effector T helper cells are responsible for mediating autoimmunity, selective inhibition of PKC- is considered a treatment for prevention of autoimmune diseases and allograft rejection.
Keywords: PKC-, T cells, TCR signaling, autoimmunity, transplantation rejection, T cell receptor, TCR, antigen presenting cells, APC, histocompatibility complex, MHC, protein tyrosine kinase, diacylglycerol, DAG, central SMAC, peripheral SMAC, distal SMAC, Activationinduced cell death, airway hyperresponsiveness, myelin oligodendrocyte glycoprotein, MOG, experimental autoimmune encephalitis, EAE, collagen-induced arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Volume: 10 Issue: 4
Author(s): Myung-Ja Kwon, Ruiqing Wang, Jian Ma and Zuoming Sun
Affiliation:
Keywords: PKC-, T cells, TCR signaling, autoimmunity, transplantation rejection, T cell receptor, TCR, antigen presenting cells, APC, histocompatibility complex, MHC, protein tyrosine kinase, diacylglycerol, DAG, central SMAC, peripheral SMAC, distal SMAC, Activationinduced cell death, airway hyperresponsiveness, myelin oligodendrocyte glycoprotein, MOG, experimental autoimmune encephalitis, EAE, collagen-induced arthritis
Abstract: Protein kinase C theta (PKC-) is a key kinase in mediating T cell receptor (TCR) signals. PKC- activated by T cell receptor (TCR) engagement translocates to immunological synapses and regulates the activation of transcriptional factors NF-κB, AP-1, and NFAT. These transcription factors then activate target genes such as IL-2. T cells deficient in PKC- display defects in T cell activation, survival, activation-induced cell death, and the differentiation into inflammatory T cells, both in vitro and in vivo. Since these effector T helper cells are responsible for mediating autoimmunity, selective inhibition of PKC- is considered a treatment for prevention of autoimmune diseases and allograft rejection.
Export Options
About this article
Cite this article as:
Kwon Myung-Ja, Wang Ruiqing, Ma Jian and Sun Zuoming, PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/1871530311006040367
DOI https://dx.doi.org/10.2174/1871530311006040367 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) HSP60 is a Ubiquitous Player in the Physiological and Pathogenic Interactions between the Chaperoning and the Immune Systems
Current Immunology Reviews (Discontinued) Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Current Pharmaceutical Design CCL17/Thymus and Activation-Related Chemokine: A biomarker for Churg-Strauss Syndrome?
Current Biomarkers (Discontinued) Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Thiol-Dependent Cathepsins: Pathophysiological Implications and Recent Advances in Inhibitor Design
Current Pharmaceutical Design Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Food Ingredients and Lipid Mediators
Current Nutrition & Food Science Generation of Regulatory T Cells to Antigen Expressed in the Retina
Current Immunology Reviews (Discontinued) Celastrol and Terpenes as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Preface [Hot Topic: Transcription Factors as Targets of Novel Therapeutic Approaches of Autoimmune Diseases (Executive Editor: Gunther Ne)]
Current Pharmaceutical Design Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis
Current Pharmaceutical Design A Neutralization scFv Antibody against IL-1β Isolated from a NIPA-based Bacterial Display Library
Current Pharmaceutical Biotechnology Transplantation of Genetically Modified Haematopoietic Stem Cells to Induce Antigen-Specific Tolerance as a Cure for Autoimmune Diseases
Current Stem Cell Research & Therapy TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design